Hedgehog Pathway Inhibitors Market: 71% of Growth to Originate from North America, BCC Segment to be Significant for Revenue Generation - Technavio

Hedgehog Pathway Inhibitors Market: Driver

• The high-risk factors for BCC and AML are the key drivers fueling the hedgehog pathway inhibitors market growth. 
• Intense exposure to UV radiation from sunlight can lead to damage to the DNA of skin cells. Significantly, a rise in the exposure duration increases the chances of developing BCC. It was estimated that approximately 90% of all non-melanoma cancer types, including BCC, are associated with direct exposure to UV radiation from sunlight.
•  Similarly, indoor tanning also increases the risk of developing BCC due to a reduction in melanin synthesis. Individuals who are exposed to heavy chemicals have a greater chance of developing carcinomas compared with others. Long-term exposure to benzene and formaldehyde is a risk factor for AML. Such risk factors are increasing the prevalence of BCC and AML, which is expected to fuel the demand for Hedgehog pathway inhibitors during the forecast period.

Hedgehog Pathway Inhibitors Market: Trends

• The development of repurposed formulations is one of the key hedgehog pathway inhibitors market trends propelling the market growth.
•  Drug repurposing is an affordable and safe treatment approach to reuse the available approved non-cancer drugs as new anticancer treatments. It can make clinically important contributions to oncology.
• For instance, itraconazole is already approved by the US FDA to treat fungal infections by inhibiting the 14-alpha demethylase. Inhibitor Therapeutics Inc., formerly known as HedgePath Pharmaceuticals Inc., in collaboration with Mayne Pharma Group Ltd., developed a repurposed formulation of itraconazole, namely SUBA-Itraconazole. SUBA technology enhances the bioavailability of poorly soluble approved drugs. The technology uses a solid dispersion of the drug in a polymer to increase the absorption of drugs in the gastrointestinal tract to attain super bioavailability. Such developments will propel the market growth during the forecast period.

To know about other drivers & trends along with market challenges - Request a Free Sample

Hedgehog Pathway Inhibitors Market: Segmentation Analysis

The market research report segments the hedgehog pathway inhibitors market by Geography (North America, Europe, Asia, and the Rest of the World (ROW)).

• Revenue Generating Segment - The hedgehog pathway inhibitors market share growth by the BCC segment will be significant during the forecast period.
• The growth of the BCC segment is primarily driven by the increasing prevalence of BCC and the presence of various risk factors, including exposure to UV radiation and chemicals, as well as smoking. However, the segment is expected to face a major threat from the high cost of drugs and the availability of highly effective substitutes. At the same time, factors such as the availability of patient assistance programs from vendors are expected to reduce the financial burden on patients. These factors will propel the segment growth during the forecast period.
• To know about the market contribution of each segment - Request a Free sample report

The competitive scenario provided in the Hedgehog Pathway Inhibitors Market report analyzes, evaluates, and positions companies based on various performance indicators. Some of the factors considered for this analysis include the financial performance of companies over the past few years, growth strategies, product innovations, new product launches, investments, growth in market share, etc. Don't wait, Make a strategic approach & boost your business goals with our Hedgehog Pathway Inhibitors Market Forecast Report -  Buy Now!

Related Reports:

• The sexual enhancement supplements market share is expected to increase by USD 407.16 million from 2019 to 2024, and the market's growth momentum will accelerate at a CAGR of 9%.
• The fertility supplements market share is expected to increase to USD 819.22 million from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 7.53%.

Browse for Technavio "Healthcare Market" Research Reports

Table of Content

1 Executive Summary

• 1.1 Market Overview
• Exhibit 01: Executive Summary – Chart on Market Overview
• Exhibit 02: Executive Summary – Data Table on Market Overview
• Exhibit 03: Executive Summary – Chart on Global Market Characteristics
• Exhibit 04: Executive Summary – Chart on Market by Geography
• Exhibit 05: Executive Summary – Chart on Market Segmentation by Indication
• Exhibit 06: Executive Summary – Chart on Incremental Growth
• Exhibit 07: Executive Summary – Data Table on Incremental Growth
• Exhibit 08: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

• 2.1 Market ecosystem
• Exhibit 09: Parent market
• Exhibit 10: Market Characteristics

3 Market Sizing

• 3.1 Market definition
• Exhibit 11: Offerings of vendors included in the market definition

• 3.2 Market segment analysis
• Exhibit 12: Market segments

• 3.3 Market size 2021

• 3.4 Market outlook: Forecast for 2021-2026
• Exhibit 13: Chart on Global - Market size and forecast 2021-2026 ($ million)
• Exhibit 14: Data Table on Global - Market size and forecast 2021-2026 ($ million)
• Exhibit 15: Chart on Global Market: Year-over-year growth 2021-2026 (%)
• Exhibit 16: Data Table on Global Market: Year-over-year growth 2021-2026 (%)

4 Five Forces Analysis

• 4.1 Five forces summary
• Exhibit 17: Five forces analysis - Comparison between 2021 and 2026

• 4.2 Bargaining power of buyers
• Exhibit 18: Chart on Bargaining power of buyers – Impact of key factors 2021 and 2026

• 4.3 Bargaining power of suppliers
• Exhibit 19: Bargaining power of suppliers – Impact of key factors in 2021 and 2026

• 4.4 Threat of new entrants
• Exhibit 20: Threat of new entrants – Impact of key factors in 2021 and 2026

• 4.5 Threat of substitutes
• Exhibit 21: Threat of substitutes – Impact of key factors in 2021 and 2026

• 4.6 Threat of rivalry
• Exhibit 22: Threat of rivalry – Impact of key factors in 2021 and 2026

• 4.7 Market condition
• Exhibit 23: Chart on Market condition - Five forces 2021 and 2026

5 Market Segmentation by Indication

• 5.1 Market segments
• Exhibit 24: Chart on Indication - Market share 2021-2026 (%)
• Exhibit 25: Data Table on Indication - Market share 2021-2026 (%)

• 5.2 Comparison by Indication
• Exhibit 26: Chart on Comparison by Indication
• Exhibit 27: Data Table on Comparison by Indication

• 5.3 BCC - Market size and forecast 2021-2026
• Exhibit 28: Chart on BCC - Market size and forecast 2021-2026 ($ million)
• Exhibit 29: Data Table on BCC - Market size and forecast 2021-2026 ($ million)
• Exhibit 30: Chart on BCC - Year-over-year growth 2021-2026 (%)
• Exhibit 31: Data Table on BCC - Year-over-year growth 2021-2026 (%)

• 5.4 AML - Market size and forecast 2021-2026
• Exhibit 32: Chart on AML - Market size and forecast 2021-2026 ($ million)
• Exhibit 33: Data Table on AML - Market size and forecast 2021-2026 ($ million)
• Exhibit 34: Chart on AML - Year-over-year growth 2021-2026 (%)
• Exhibit 35: Data Table on AML - Year-over-year growth 2021-2026 (%)

• 5.5 Market opportunity by Indication
• Exhibit 36: Market opportunity by Indication ($ million)

6 Customer Landscape

• 6.1 Customer landscape overview
• Exhibit 37: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

7 Geographic Landscape

• 7.1 Geographic segmentation
• Exhibit 38: Chart on Market share by geography 2021-2026 (%)
• Exhibit 39: Data Table on Market share by geography 2021-2026 (%)

• 7.2 Geographic comparison
• Exhibit 40: Chart on Geographic comparison
• Exhibit 41: Data Table on Geographic comparison

• 7.3 North America - Market size and forecast 2021-2026
• Exhibit 42: Chart on North America - Market size and forecast 2021-2026 ($ million)
• Exhibit 43: Data Table on North America - Market size and forecast 2021-2026 ($ million)
• Exhibit 44: Chart on North America - Year-over-year growth 2021-2026 (%)
• Exhibit 45: Data Table on North America - Year-over-year growth 2021-2026 (%)

• 7.4 Europe - Market size and forecast 2021-2026
• Exhibit 46: Chart on Europe - Market size and forecast 2021-2026 ($ million)
• Exhibit 47: Data Table on Europe - Market size and forecast 2021-2026 ($ million)
• Exhibit 48: Chart on Europe - Year-over-year growth 2021-2026 (%)
• Exhibit 49: Data Table on Europe - Year-over-year growth 2021-2026 (%)

• 7.5 Asia - Market size and forecast 2021-2026
• Exhibit 50: Chart on Asia - Market size and forecast 2021-2026 ($ million)
• Exhibit 51: Data Table on Asia - Market size and forecast 2021-2026 ($ million)
• Exhibit 52: Chart on Asia - Year-over-year growth 2021-2026 (%)
• Exhibit 53: Data Table on Asia - Year-over-year growth 2021-2026 (%)

• 7.6 Rest of World (ROW) - Market size and forecast 2021-2026
• Exhibit 54: Chart on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
• Exhibit 55: Data Table on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
• Exhibit 56: Chart on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
• Exhibit 57: Data Table on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)

• 7.7 US - Market size and forecast 2021-2026
• Exhibit 58: Chart on US - Market size and forecast 2021-2026 ($ million)
• Exhibit 59: Data Table on US - Market size and forecast 2021-2026 ($ million)
• Exhibit 60: Chart on US - Year-over-year growth 2021-2026 (%)
• Exhibit 61: Data Table on US - Year-over-year growth 2021-2026 (%)

• 7.8 Canada - Market size and forecast 2021-2026
• Exhibit 62: Chart on Canada - Market size and forecast 2021-2026 ($ million)
• Exhibit 63: Data Table on Canada - Market size and forecast 2021-2026 ($ million)
• Exhibit 64: Chart on Canada - Year-over-year growth 2021-2026 (%)
• Exhibit 65: Data Table on Canada - Year-over-year growth 2021-2026 (%)

• 7.9 Germany - Market size and forecast 2021-2026
• Exhibit 66: Chart on Germany - Market size and forecast 2021-2026 ($ million)
• Exhibit 67: Data Table on Germany - Market size and forecast 2021-2026 ($ million)
• Exhibit 68: Chart on Germany - Year-over-year growth 2021-2026 (%)
• Exhibit 69: Data Table on Germany - Year-over-year growth 2021-2026 (%)

• 7.10 UK - Market size and forecast 2021-2026
• Exhibit 70: Chart on UK - Market size and forecast 2021-2026 ($ million)
• Exhibit 71: Data Table on UK - Market size and forecast 2021-2026 ($ million)
• Exhibit 72: Chart on UK - Year-over-year growth 2021-2026 (%)
• Exhibit 73: Data Table on UK - Year-over-year growth 2021-2026 (%)

• 7.11 China - Market size and forecast 2021-2026
• Exhibit 74: Chart on China - Market size and forecast 2021-2026 ($ million)
• Exhibit 75: Data Table on China - Market size and forecast 2021-2026 ($ million)
• Exhibit 76: Chart on China - Year-over-year growth 2021-2026 (%)
• Exhibit 77: Data Table on China - Year-over-year growth 2021-2026 (%)

• 7.12 Market opportunity by geography
• Exhibit 78: Market opportunity by geography ($ million)

8 Drivers, Challenges, and Trends

• 8.1 Market drivers

• 8.2 Market challenges

• 8.3 Impact of drivers and challenges
• Exhibit 79: Impact of drivers and challenges in 2021 and 2026

• 8.4 Market trends

9 Vendor Landscape

• 9.1 Overview

• 9.2 Vendor landscape
• Exhibit 80: Overview on Criticality of inputs and Factors of differentiation

• 9.3 Landscape disruption
• Exhibit 81: Overview on factors of disruption

• 9.4 Industry risks
• Exhibit 82: Impact of key risks on business

10 Vendor Analysis

• 10.1 Vendors covered
• Exhibit 83: Vendors covered

• 10.2 Market positioning of vendors
• Exhibit 84: Matrix on vendor position and classification

• 10.3 BridgeBio Pharma Inc.
• Exhibit 85: BridgeBio Pharma Inc. - Overview
• Exhibit 86: BridgeBio Pharma Inc. - Product / Service
• Exhibit 87: BridgeBio Pharma Inc. - Key news
• Exhibit 88: BridgeBio Pharma Inc. - Key offerings

• 10.4 Bristol Myers Squibb Co.
• Exhibit 89: Bristol Myers Squibb Co. - Overview
• Exhibit 90: Bristol Myers Squibb Co. - Product / Service
• Exhibit 91: Bristol Myers Squibb Co. - Key offerings

• 10.5 F. Hoffmann La Roche Ltd.
• Exhibit 92: F. Hoffmann La Roche Ltd. - Overview
• Exhibit 93: F. Hoffmann La Roche Ltd. - Business segments
• Exhibit 94: F. Hoffmann La Roche Ltd. - Key news
• Exhibit 95: F. Hoffmann La Roche Ltd. - Key offerings
• Exhibit 96: F. Hoffmann La Roche Ltd. - Segment focus

• 10.6 Inhibitor Therapeutics Inc
• Exhibit 97: Inhibitor Therapeutics Inc - Overview
• Exhibit 98: Inhibitor Therapeutics Inc - Product / Service
• Exhibit 99: Inhibitor Therapeutics Inc - Key offerings

• 10.7 MAX BioPharma Inc.
• Exhibit 100: MAX BioPharma Inc. - Overview
• Exhibit 101: MAX BioPharma Inc. - Product / Service
• Exhibit 102: MAX BioPharma Inc. - Key offerings

• 10.8 Mayne Pharma Group Ltd.
• Exhibit 103: Mayne Pharma Group Ltd. - Overview
• Exhibit 104: Mayne Pharma Group Ltd. - Business segments
• Exhibit 105: Mayne Pharma Group Ltd. - Key news
• Exhibit 106: Mayne Pharma Group Ltd. - Key offerings
• Exhibit 107: Mayne Pharma Group Ltd. - Segment focus

• 10.9 Novartis AG
• Exhibit 108: Novartis AG - Overview
• Exhibit 109: Novartis AG - Business segments
• Exhibit 110: Novartis AG - Key offerings
• Exhibit 111: Novartis AG - Segment focus

• 10.10 Pfizer Inc.
• Exhibit 112: Pfizer Inc. - Overview
• Exhibit 113: Pfizer Inc. - Product / Service
• Exhibit 114: Pfizer Inc. - Key news
• Exhibit 115: Pfizer Inc. - Key offerings

• 10.11 Sanofi
• Exhibit 116: Sanofi - Overview
• Exhibit 117: Sanofi - Business segments
• Exhibit 118: Sanofi - Key news
• Exhibit 119: Sanofi - Key offerings
• Exhibit 120: Sanofi - Segment focus

• 10.12 Sun Pharmaceutical Industries Ltd.
• Exhibit 121: Sun Pharmaceutical Industries Ltd. - Overview
• Exhibit 122: Sun Pharmaceutical Industries Ltd. - Product / Service
• Exhibit 123: Sun Pharmaceutical Industries Ltd. - Key offerings

11 Appendix

• 11.1 Scope of the report

• 11.2 Inclusions and exclusions checklist
• Exhibit 124: Inclusions checklist
• Exhibit 125: Exclusions checklist

• 11.3 Currency conversion rates for US$
• Exhibit 126: Currency conversion rates for US$

• 11.4 Research methodology
• Exhibit 127: Research methodology
• Exhibit 128: Validation techniques employed for market sizing
• Exhibit 129: Information sources

• 11.5 List of abbreviations
• Exhibit 130: List of abbreviations

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com/

SOURCE Technavio